Multiple Sclerosis and Related Disorders, Journal Year: 2024, Volume and Issue: 88, P. 105702 - 105702
Published: June 5, 2024
Language: Английский
Annals of Neurology, Journal Year: 2025, Volume and Issue: unknown
Published: April 19, 2025
Objective To compare clinical and radiological outcomes among relapsing multiple sclerosis patients treated with autologous hematopoietic stem cell transplantation (AHSCT), alemtuzumab (ATZ), ocrelizumab (OCR). Methods From a London (UK) hospital‐based observational cohort, modeled data were obtained from 621 relapsing–remitting patients, who AHSCT (n = 103), ATZ 204), OCR 314), followed up for 43, 32 median months, respectively. The annualized relapse rate, new magnetic resonance imaging (MRI) lesions, disability progression on Expanded Disability Status Scale assessed. Results showed superior efficacy compared OCR. After 5‐year follow up, the mean rate (0.026 vs 0.087; p < 0.001), risk of relapses (HR 0.29, 95% CI 0.13–0.63; 0.002), MRI activity 0.33, 0.15–0.72; 0.006) significantly lower in versus group. Compared OCR, after 3‐year follow‐up (0.028 0.073; 0.02) trend to reduced 0.45, 0.18–1.14; 0.09), but similar low rates (6%) 0.86, 0.28–2.67; 0.80). In addition, there was AHSCT, both 1.19, 0.71–2.00; 0.50) 1.08, 0.57–2.04; 0.82) groups. Interpretation by greater prevention suppressed more profoundly than ATZ, similarly albeit shorter up. accumulating Studies larger sample sizes longer may enable confirmation these findings or detection any additional differential effects. ANN NEUROL 2025
Language: Английский
Citations
0
Frontiers in Cellular Neuroscience, Journal Year: 2022, Volume and Issue: 16
Published: May 26, 2022
Hematopoietic stem cells have been investigated and applied for the treatment of certain neurological disorders a long time. Currently, their therapeutic potential is harnessed in autologous allogeneic hematopoietic cell transplantation (HSCT). Autologous HSCT helpful immune-mediated diseases such as Multiple Sclerosis. However, clinical benefits derive more from immunosuppressive conditioning regimen than interaction between nervous system. Mainly used hematologic malignancies, explores donor-derived cells. In setting, it has proven to be most valuable Inborn Errors Metabolism, large spectrum multisystem characterized by congenital deficiencies enzymes involved metabolic pathways. Metabolism X-linked Adrenoleukodystrophy present with brain accumulation enzymatic substrates that result progressive inflammatory demyelination. Allogeneic can halt ongoing neural destruction replacing hematopoietic-originated microglia myeloid precursors. Microglia, only successfully transplanted thus far, are source central system correction play significant role crosstalk After transplantation, engrafted modulate microenvironment recapitulating microglial functions enhancing repair mechanisms remyelination. some disorders, additional donor secretome cross-corrects neighboring via mannose-6-phosphatase paracrine The limitations this setting relate slow turnover complications graft-vs.-host disease. These restraints accelerated development gene therapy, where collected, manipulated ex vivo overexpress missing enzyme, infused back into patient. With cellular drug vehicle strategy, populated improved exposed supraphysiological levels flawed protein, resulting correction. This review focuses on therapy Metabolism. A brief mention will also made treated approach.
Language: Английский
Citations
17
European Neurology, Journal Year: 2023, Volume and Issue: 86(4), P. 263 - 276
Published: Jan. 1, 2023
Background: The SARS-CoV-2 pandemic represents one of the most challenging issues that have recently influenced everyday life in countries all over world. Understanding risk this disease is high importance patients with multiple sclerosis (MS) as they represent a vulnerable population through their treatment disease-modifying therapies (DMTs). Infective episodes may trigger relapses and lead to deterioration health condition. Summary: Vaccination an important preventive measure against infectious diseases. In MS patients, concerns been raised about effectiveness vaccines on various immunomodulatory drugs possible adverse effects including impairment neurological functions. objectives article were summarize current knowledge immune responses COVID-19 safety provide practical guidance based data available date. Key Messages: Although not associated higher COVID-19, infection can or pseudo-relapses. Vaccines are recommended for who active phase disease, despite fact there still lack long-term reliable COVID-19. Some DMTs reduce vaccine humoral responses, but might some protection adequate T-cell response. To optimize vaccination, ideal timing application dosing regimen crucial.
Language: Английский
Citations
9
Nature Reviews Neurology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 15, 2025
Language: Английский
Citations
0
Current Neurology and Neuroscience Reports, Journal Year: 2023, Volume and Issue: 23(9), P. 507 - 520
Published: Aug. 17, 2023
Abstract Purpose of Review Autologous haematopoietic stem cell transplantation (AHSCT) is increasingly considered a treatment option for patients with multiple sclerosis (MS), an autoimmune demyelinating and degenerative disease the central nervous system (CNS). AHSCT persistently suppresses inflammation improves course in large proportions relapsing–remitting (RR) MS. Aim this article to review relevant new knowledge published during last 3 years. Recent Findings Laboratory studies reported confirmatory insights into immunological biomarker effects AHSCT. Retrospective clinical confirmed excellent outcomes RRMS, showing possible superior effectiveness over standard therapies suggesting benefit early secondary progressive (SP) MS inflammatory features. New data on risks infertility autoimmunity were also reported. Summary Further evidence high acceptable safety strengthens its position as aggressive RRMS. research needed better define role treatment-naïve forms MS, ideally within randomised trials (RCTs).
Language: Английский
Citations
9
Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13
Published: Sept. 12, 2022
Development of disease-modifying therapies including monoclonal antibody (mAb)-based therapeutics for the treatment multiple sclerosis (MS) has been extremely successful over past decades. Most mAb-based approved MS deplete immune cell subsets and act through activation cellular Fc-gamma receptors expressed by cytotoxic lymphocytes phagocytes, resulting in antibody-dependent cytotoxicity or initiation complement-mediated cytotoxicity. The therapeutic goal is to eliminate pathogenic components potentially foster reconstitution a new healthy system. Ab-mediated depletion include CD52-targeting mAb alemtuzumab, CD20-specific therapeutics, Ab-based treatments which are currently being developed tested clinical trials. Here, we review recent developments effector mechanisms applications therapies, compare their immunological effects with prototypic strategy, autologous hematopoietic stem transplantation, discuss potential restore tolerance achieve durable remission people MS.
Language: Английский
Citations
13
Combinatorial Chemistry & High Throughput Screening, Journal Year: 2024, Volume and Issue: 27(15), P. 2170 - 2179
Published: Jan. 21, 2024
Osteoarthritis (OA) is a degenerative disease that results in constriction of the joint space due to gradual deterioration cartilage, alterations subchondral bone, and synovial membrane. Recently, scientists have found OA involves lesions whole joint, addition wear tear cartilage damage. often accompanied by subclinical form synovitis, which chronic, relatively low-grade inflammatory response mainly mediated innate immune system. The "immune-joint" axis refers an interaction with inflammation range. Previous studies underestimated role immune-joint OA, there no related research. For this reason, review aimed evaluate existing evidence on influence mechanisms pathogenesis OA. system body's first line defense. When triggered, it instantly activates downstream signal pathway, causing response, while also promoting cells invade tissue accelerate progression We proposed concept explored from two aspects Traditional Chinese Medicine (TCM) theory modern medical research, such as immunity macrophages complement other enrich scientific connotation axis.
Language: Английский
Citations
2
Current Neuropharmacology, Journal Year: 2024, Volume and Issue: 22(8), P. 1286 - 1326
Published: Jan. 25, 2024
Abstract: Multiple sclerosis (MS) is the most prevalent chronic autoimmune inflammatory- demyelinating disorder of central nervous system (CNS). It usually begins in young adulthood, mainly between second and fourth decades life. Usually, clinical course characterized by involvement multiple CNS functional systems different, often overlapping phenotypes. In last decades, remarkable results have been achieved treatment MS, particularly relapsing- remitting (RRMS) form, thus improving long-term outcome for many patients. As deeper knowledge MS pathogenesis respective molecular targets keeps growing, nowadays, several lines disease-modifying treatments (DMT) are available, an impressive change compared to relative poverty options available past. Current management DMTs aimed at reducing relapse frequency, ameliorating symptoms, preventing disability progression. Notwithstanding relevant increase pharmacological RRMS, research now increasingly pointing identify new molecules with high efficacy, progressive forms. Hence, future efforts should be concentrated on achieving a more extensive, if not exhaustive, understanding pathogenetic mechanisms underlying this phase disease order characterize novel therapeutic intervention. The purpose review provide compact overview numerous currently approved innovative approaches, including neuroprotective as anti-LINGO-1 monoclonal antibody cell therapies, effective safe potentially leading cure disease.
Language: Английский
Citations
2
Scientific Reports, Journal Year: 2022, Volume and Issue: 12(1)
Published: Sept. 13, 2022
In this study, we aimed to assess the quality of life, fatigue, anxiety, and depression after Autologous haematopoietic stem cell transplantation (AHSCT) investigate its impact on separate domains health status fatigue in patients with multiple sclerosis (MS). Overall, 18 highly active relapsing MS (mean age 36.3 years, 83.3% female) underwent AHSCT Vilnius Multiple Sclerosis center, prospectively collected Short Form 36, Health Survey Questionnaire, Fatigue Descriptive Scale, Hospital Anxiety Depression Scale beforeand Month3, 12, 24 AHSCT. The median score Expanded Disability Status at Month3 transplant improved 14 (77.8%). A significant improvement physical functioning, vitality, pain was found (p < 0.05), which sustained until Month12 24. AHSCT, Month24. Decrease EDSS had a positive better HRQoL outcomes, especially social outcomes. Thus, life reduced symptoms MS. determined earlier QoL than fatigue.
Language: Английский
Citations
11
Cells, Journal Year: 2022, Volume and Issue: 11(21), P. 3346 - 3346
Published: Oct. 24, 2022
Systemic sclerosis (SSc) is a systemic disease characterized by autoimmune responses, vasculopathy and tissue fibrosis. The pathogenic mechanisms involve wide range of cells soluble factors. complexity interactions leads to heterogeneous clinical features in terms the extent, severity, rate progression skin fibrosis internal organ involvement. Available disease-modifying drugs have only modest effects on halting may be associated with significant side effects. Therefore, cellular therapies been developed aiming at restoration immunologic self-tolerance order provide durable remissions or foster regeneration. Currently, SSc recommended as ‘standard indication’ for autologous hematopoietic stem cell transplantation European Society Blood Marrow Transplantation. This review provides an overview SSc, from pre-clinical models applications, opening towards more advanced therapies, such mesenchymal cells, regulatory T potentially CAR-T-cell therapies.
Language: Английский
Citations
11